Jazz Pharmaceuticals plc — Director's Dealing 2024

Jan 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2024-01-17

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-17	Ordinary Shares	A	1327	$0.0	Acquired	7363	Direct

Footnotes

F1: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified.

F2: The Reporting Person acquired 50 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 30, 2023.